Cara Ferreira
Chief Executive Officer Lumina Pharm
Dr. Cara Ferreira, PhD, MBA is currently the CEO of Lumina Pharmaceuticals a clinical-stage radiopharmaceutical company distinguished by its innovative technology targeting novel biomarkers to treat cancer. Most recently she was an executive at Fusion Pharmaceuticals a clinical stage company focused on targeted alpha therapy which was acquired by AstraZeneca in June 2024. Previously, Cara was an Associate Partner at McKinsey & Company, where she led strategy consulting for global pharmaceutical clients. Dr. Ferreira has been active in the radiopharmaceutical space for 25+ years and has held leadership roles in SNMMI.
Seminars
Wednesday 25th February 2026
Targeting the Extracellular Matrix: Overcoming Biological Barriers to Unlock Novel Therapeutic Opportunities
1:00 pm
- Analyzing why components of the extracellular matrix (ECM) could be ideal targets for radioligand therapy
- Exploring challenges associated with delivering therapeutic doses when targeting components of the ECM
- Reviewing early development strategy for a novel fibrin targeted radioligand therapy
New Company for 2026
